ClinicalTrials.gg
RecruitingNCT06807983LUCREEDUpdated Dec 4, 2025

LUng and Cardiac Ultrasound for REspiratory Distress in ElDerly

An interventional study of diagnostic strategy based on lung and cardiac ultrasonography in Dyspnea and Respiratory Distress Syndrome, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 124 studies in Dyspnea with a site in France — 33 open to participants now, 34 under way, none of them phase 3. Dyspnea · France.

Planned enrollment
10th of 66
504 · median 64
Started
2025
with 9 others
No phase
51 of 124
17 open now
Primary completion
2027-05
later than 20 of 33 live
Registered
103rd of 124
by date
Lead sponsor
5 of 124
University Hospital, Toulouse

Among the 124 studies in Dyspnea with a site in France, this one is the 10th largest by planned enrollment of the 66 interventional ones that give a count, is one of 10 that started in 2025, is one of 51 with no phase, reaches primary completion later than 20 of the 33 other live ones, and was the 103rd registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

33 of the 124 studies in Dyspnea with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Dyspnea with a site in France, or all of them as a file.
02

Study summary

Prospective trial to evaluate the impact on the initial therapeutic inadequacy of a management strategy for acute dyspnea in the elderly based on the use of lung and cardiac ultrasonography.

Read the detailed description

Acute dyspnea is a frequent and serious reason of admission in Emergency Department (ED), with a one-month mortality close to 16%. It is difficult to diagnose in the initial assessment phase since the cause of this symptom can vary (cardiological, pulmonary, infectious, etc.) and the symptoms can be misleading. This difficulty in diagnosing delays the implementation of appropriate therapeutic management even as the timeliness of management is associated with a reduction in mortality. These issues are particularly important in the elderly.

Lung and cardiac ultrasonography performed by the emergency physician, immediately available at the patient's bedside, could reduce the diagnostic and therefore therapeutic delay.

However, the impact of a diagnostic strategy based on lung and cardiac ultrasonography in dyspneic elderly subjects has not been evaluated.

Patients will be randomized in two groups : "standard of care" or "clinical ultrasound" group. Treatments initiated in Emergency Department (ED) will be noted to be compared to final diagnosis.

03

Conditions studied

  • Dyspnea
  • Respiratory Distress Syndrome

Keywords

  • Elderly
  • Point-of-Care Ultrasound
  • Respiratory Distress Syndrom
  • Dyspnea
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients will be aged over 65 years, affiliated with the French social security system, and presenting to the ED with acute dyspnea (onset \<14 days) accompanied by severity signs before or at triage (respiratory rate ≥22 and SpO2 \<92% on room air). The enrolling emergency physician (EP) must be the patient's treating physician and must be trained in LuCUS. Written from the patient or their legal representative is required for inclusion

Exclusion criteria

Exclusion Criteria:

dyspnea secondary to thoracic trauma, dyspnea clearly related to COVID-19, known pulmonary fibrosis or lung cancer, prior administration of specific treatment for dyspnea before inclusion, immediate need for endotracheal intubation, patients identified as being at end-of-life, and individuals under legal guardianship or deprived of liberty.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
504 participants (estimated)

Study arms

  • Experimental
    clinical ultrasound

    diagnostic strategy based on the protocolized implementation of clinical lung and cardiac ultrasonography, with a proposed diagnostic and therapeutic focus based on the results.

    Diagnostic Test: diagnostic strategy based on lung and cardiac ultrasonography

  • No intervention
    standard care

    diagnostic and therapeutic strategy based on the usual practices of the department and the clinician

Interventions

  • Diagnostic testdiagnostic strategy based on lung and cardiac ultrasonography

    cardiopulmonary ultrasound performed by the emergency physician, immediately at patient's bed

06

What researchers measure

Primary outcomes

  1. therapeutic inadequacy

    therapeutic inadequacy between initiated emergency treatments and the final diagnosis made by expert opinion

    Time frame: Hour 1

Secondary outcomes

  1. correct diagnosis

    correct diagnosis at the emergency department discharge (compared with final diagnosis made by expert opinion)

    Time frame: emergency department discharge (up to hour 4)

  2. duration of emergency department stay

    duration in emergency department (in hours)

    Time frame: emergency department discharge (up to hour 4)

  3. Post-emergency hospital stay

    duration in Post-emergency hospital department: in medicine/surgery/obstetrics or follow-up and rehabilitation care (in days)

    Time frame: Day 30

  4. Number of days alive outside hospital between D0 and D30

    Number of days alive outside hospital between D0 and D30

    Time frame: Day 30

  5. Care cost

    Care cost - Direct and indirect medical cost looking at French social security spendings for patients

    Time frame: Day 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Balen F, Hebrard M, Delmas C, Dubucs X, Noel-Savina E, Costa N, Shourick J; LUC REED investigators; and the LUC REED investigators. Lung and cardiac ultrasound for respiratory distress in the elderly: study protocol of the LUC REED stepped-wedge cluster randomised trial. BMJ Open. 2025 Aug 16;15(8):e104715. doi: 10.1136/bmjopen-2025-104715. PubMed 40819865 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 17 months after the start.

Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 17 months is above that.

Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Feb 4, 2025
StartActual
Nov 4, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06807983
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Nov 4, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Manon Hebrard
Contact
hebrard.m@chu-toulouse.fr
561322271 ext. +33
Frédéric BALEN, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion